HOME >> BIOLOGY >> NEWS
Potent new compound from blue-green algae may help treat, elucidate nerve disorders

Click here for abstract.

HONOLULU, Dec. 19 - Amid a growing list of biologically useful chemicals from the sea, a newly discovered compound - kalkitoxin - stands out for its potential to help researchers understand nerve function, which could someday lead to new treatments for pain, epilepsy and possibly stroke. The finding was reported here today at the 2000 International Chemical Congress of Pacific Basin Societies.

The weeklong scientific meeting, held once every five years, is hosted by the American Chemical Society, in conjunction with its counterparts in Australia, Canada, Japan and New Zealand.

Lead investigator William Gerwick, Ph.D., a pharmacy professor at Oregon State University in Corvallis, says the neurotoxin - a metabolite in cyanobacteria - is fundamentally new in both structure and potency.

"What we've found is a spectacularly potent neurotoxin, meaning kalkitoxin can kill neurons," explained Gerwick. "And when a compound is very toxic, it's working by a very specific mechanism." He and his collaborators hope to use that mechanism "to dissect neurochemical pathways and to understand how drugs affect them," he said.

Their discovery began "in an absolutely beautiful bay" of the Caribbean island of Curacao, near Venezuela, Gerwick said. "In 1994, we found a collection of cyanobacteria growing like hairs off the sea floor. We brought several liters of it back to Oregon for testing." Marine cyanobacteria, also called blue-green algae, are most familiar to many people as "pond scum."

Back in the laboratory, Gerwick's team ground up samples of the simple plant and tested extracts on brine shrimp and fish. One extract proved toxic even in concentrations of parts per billion. The researchers named the as-yet-mysterious compound after the island's Kalki Bay
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
808-944-6381
American Chemical Society
18-Dec-2000


Page: 1 2

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potent toxin reveals new antibiotic resistance mechanism
3. Potential blood test for colon cancer risk
4. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
5. Potential cause of arthritis discovered
6. Potential of regenerative medicine explored
7. Potential therapy reported for children, adults with end-stage liver disease
8. Potential allergy vaccine boosts hope for sufferers
9. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
10. Potential new anthrax therapy discovered
11. Potential gene therapy carriers created that mimic viruses, without the risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, Inc. ... focused on the licensing, development and commercialization of innovative ... Best Company in North America ... the award based on the FDA approval of ... tablets), ENTYCE ® (capromorelin oral solution) and NOCITA ...
(Date:1/20/2017)... YORK , January 20, 2017 ... current market conditions have influenced the most recent performances ... Therapeutics Inc. (NASDAQ: RGLS ), Abeona Therapeutics ... (NASDAQ: TBPH ), and Sage Therapeutics Inc. ... research report by Grand View Research, global Biotech market size is ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... (LES®) Technologies, announced today the next evolution in spinal fusion, the MISquito ... In contrast to the competition, SpineFrontier is focused on technique driven product ...
Breaking Biology Technology:
Cached News: